Literature DB >> 18353353

Antigen presentation of detergent-free glutamate decarboxylase (GAD65) is affected by human serum albumin as carrier protein.

Jordan Steed1, Lisa K Gilliam, Robert A Harris, Ake Lernmark, Christiane S Hampe.   

Abstract

The smaller isoform of glutamate decarboxylase (GAD65) is a major autoantigen in type 1 diabetes (TID). Its hydrophobic character requires detergent to keep the protein in solution, which complicates studies of antigen processing and presentation. In this study an attempt was made to replace detergent with human serum albumin (HSA) for in vitro antigen presentation. Different preparations of recombinant human GAD65 solubilized by HSA were incubated with Priess B cells (HLA DRB1*0401) and antigen presentation was tested with HLA DRB1*0401-restricted and epitope-specific T33.1 (GAD65 epitope 274-286) and T35 (GAD65 epitope 115-127) T-cell hybridomas. Specific epitope recognition by T33.1 (274-286) and T35 (115-127) cells varied between the different GAD65/HSA preparations, and a reverse pattern of antigen presentation was detected by the two hybridoma. The HSA-specific T-cell hybridoma 17.9 response to the different GAD65/HSA preparations followed the same pattern as that observed for the T33.1 cells. The content of immunoreactive GAD65 measured with four GAD65 antibodies indicated that the lowest GAD65 concentration resulted in the highest 274-286, but the lowest 115-127 presentation. This suggests that HSA-GAD65 interactions qualitatively affect the epitope specificity of GAD65 presentation. HSA may enhance the 274-286 epitope presentation, while suppressing the 115-127 epitope.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353353      PMCID: PMC2442559          DOI: 10.1016/j.jim.2008.02.006

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  32 in total

1.  A novel monoclonal antibody specific for the N-terminal end of GAD65.

Authors:  C S Hampe; P Lundgren; T L Daniels; L P Hammerle; S M Marcovina; A Lernmark
Journal:  J Neuroimmunol       Date:  2001-02-01       Impact factor: 3.478

Review 2.  Controlling the controls: GAD65 autoreactive T cells in type 1 diabetes.

Authors:  Ake Lernmark
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

Review 3.  The extraordinary ligand binding properties of human serum albumin.

Authors:  Mauro Fasano; Stephen Curry; Enzo Terreno; Monica Galliano; Gabriella Fanali; Pasquale Narciso; Stefania Notari; Paolo Ascenzi
Journal:  IUBMB Life       Date:  2005-12       Impact factor: 3.885

4.  Characterization of preparations of GAD65, proinsulin, and the islet tyrosine phosphatase IA-2 for use in detection of autoreactive T-cells in type 1 diabetes: report of phase II of the Second International Immunology of Diabetes Society Workshop for Standardization of T-cell assays in type 1 diabetes.

Authors:  M Peakman; T I Tree; J Endl; P van Endert; M A Atkinson; B O Roep
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

5.  Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes.

Authors:  C S Hampe; L P Hammerle; L Bekris; E Ortqvist; I Kockum; O Rolandsson; M Landin-Olsson; C Törn; B Persson; A Lernmark
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

6.  The World Health Organization International Collaborative Study for islet cell antibodies.

Authors:  A R Mire-Sluis; R Gaines Das; A Lernmark
Journal:  Diabetologia       Date:  2000-10       Impact factor: 10.122

7.  Diabetes Antibody Standardization Program: first assay proficiency evaluation.

Authors:  Polly J Bingley; Ezio Bonifacio; Patricia W Mueller
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

8.  Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65).

Authors:  G T Nepom; J D Lippolis; F M White; S Masewicz; J A Marto; A Herman; C J Luckey; B Falk; J Shabanowitz; D F Hunt; V H Engelhard; B S Nepom
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

Review 9.  Type 1A diabetes mellitus-associated autoimmunity.

Authors:  Edwin Liu; George S Eisenbarth
Journal:  Endocrinol Metab Clin North Am       Date:  2002-06       Impact factor: 4.741

10.  Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children.

Authors:  J Ludvigsson; L Heding; G Liedén; B Marner; A Lernmark
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-15
View more
  2 in total

Review 1.  Vaccination against type 1 diabetes.

Authors:  H E Larsson; Å Lernmark
Journal:  J Intern Med       Date:  2011-06       Impact factor: 8.989

Review 2.  Immune therapy in type 1 diabetes mellitus.

Authors:  Ake Lernmark; Helena Elding Larsson
Journal:  Nat Rev Endocrinol       Date:  2013-01-08       Impact factor: 43.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.